Login

Financial Snapshot

Revenue
TTM
$2.099B
Gross Margin
TTM
62.16%
Net Income
TTM
$402.2M
Current Assets
2026 Q1
$1.540B
Current Liabilities
2026 Q1
$479.1M
Current Ratio
2026 Q1
321.48%
Total Assets
2026 Q1
$5.782B
Total Liabilities
2026 Q1
$2.450B
Book Value
2026 Q1
3.332B
Cash
2026 Q1
$646.3M
P/E
TTM
18.29
Free Cash Flow
TTM
$403.9M

Stock Price

Loading...
Market Cap: $7.3548 Billion

About Qiagen NV

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry: Biological Products, (No Diagnostic Substances)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support